# Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

> **NCT04642547** · NA · COMPLETED · sponsor: **RenJi Hospital** · enrollment: 30 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Molecular Targeted Therapy

## Interventions

- **DRUG:** Lenvatinib and Gefitinib

## Key facts

- **NCT ID:** NCT04642547
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-02
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04642547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04642547, "Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04642547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*